Citations

Clear

3042 citation(s) found for "Kumar, S".

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
Lakshman, Arjun , Lacy, Martha Q. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Leung, Nelson , Kapoor, Prashant , Go, Ronald S. , Lin, Yi , Gonsalves, Wilson I. , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Hwa, Yi Lisa, Fonder, Amie L, Leung, Nelson , Go, Ronald S , Gonsalves, Wilson , Warsame, Rahma , Lakshman, Arjun , Russell, Stephen J , Dingli, David , Lin, Yi , Singh, Preet Paul , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | October 25, 2017 | Volume: 93 | Issue: 2 | Pages: 179-186

10.1002/ajh.24954 | PMID 29067723 Get It

AbstractExperience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE‐like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes of 141 patients with RRMM who received VPLRs at our center between 2006 and 2017 in an intent‐to‐treat analysis. Median age was 59.7 years and 66.7% of patients were male. A median of 2.2 years (range 0.02‐11.4) separated diagnosis of myeloma and inititation of VPLR. High‐risk cytogenetics were present in 52.4% patients. Patients received a median of 4 (range 1‐14) prior therapies, including stem cell transplant (SCT) in 66.7% patients. Ninety‐five (67.4%) patients received VDT PACE, 20 (14.2%) patients received VD PACE and 26 (18.4%) patients received other VPLRs. Patients received a median of 1 cycle (range 1‐9) of VPLR. We observed ≥ minimal response in 68.4%, ≥ partial response (PR) in 54.4% and ≥ very good PR in 10.3% patients. Median progression‐free survival was 3.1 months (95% CI, 1.9‐3.9) and median overall survival (OS) was 8.1 months (CI, 6.2‐9.9). One‐hundred and sixteen (82.3%) patients received some therapy after VPLR; 71 (61.2%) received systemic chemotherapy, while 45 (38.8%) underwent SCT. Median OS for those who received SCT after VPLR was 15.1 months (CI, 10.3‐20.8). Age ≥ 60 years (hazard ratio [HR] 2.3 [CI, 1.4‐3.7]; P = 0.0008) and R‐ISS III stage (HR‐ 2.4 [CI, 1.3‐4.0]; P = 0.003) predicted shorter OS in patients receiving VPLR. VPLRs are effective in heavily pre‐treated RRMM. In fit patients, SCT can be used to consolidate the response to VPLR.
Combination therapy incorporating Bcl‐2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
Gonsalves, Wilson I. , Kumar, Shaji , Buadi, Francis K. , Gonsalves, Wilson

Mayo Clinic

European Journal of Haematology | October 24, 2017 | Volume: 100 | Issue: 2 | Pages: 215-217

10.1111/ejh.12986 | PMID 29064593 Get It

AbstractPrimary plasma cell leukemia (pPCL) is the most aggressive form of the plasma cell (PC) malignancy, multiple myeloma (MM). It has been commonly associated with the presence of a chromosome translocation involving the immunoglobulin heavy chain (IgH) locus on 14q32, that is t (11;14). Results from early phase clinical trials utilizing the selective Bcl‐2 inhibitor, venetoclax, as a single agent in patients with relapsed MM have had remarkable efficacy among patients with t (11;14) abnormality. The present case demonstrates the ability of a combination regimen incorporating Bcl‐2 inhibition with daratumumab, bortezomib, venetoclax, and dexamethasone to induce a rapid and very deep hematologic response in a pPCL patient with t (11;14), even in a setting of very refractory disease. This case highlights the need to further study Bcl‐2 inhibition‐based therapy as an option for therapy in patients with pPCL with t (11;14).
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Avet‐Loiseau, Hervé , Masszi, Tamás , Viterbo, Luísa, Pour, Luděk, Palumbo, Antonio , Cavo, Michèle , Langer, Christian , Pluta, Andrzej, Nagler, Arnon , Kumar, Shaji , Ben‐Yehuda, Dina, Miguel, Jesús F. San , Berg, Deborah, Lin, Jianchang , Velde, Helgi van de , Esseltine, Dixie‐Lee, Bacco, Alessandra Di , Moreau, Philippe , Richardson, Paul G. , Moreau, Philippe , San-Miguel, Jesus , Masszi, Tamas , Bahlis, Nizar Jacques , Chng, Wee Joo , Ganly, Peter S. , Rajkumar, S. Vincent , Esseltine, Dixie‐Lee, Richardson, Paul Gerard Guy

Mayo Clinic

Blood | October 20, 2017 | Volume: 130 | Issue: 24 | Pages: 2610-2618

10.1182/blood-2017-06-791228 | PMID 29054911 Get It

Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patients with RRMM.
Determinants of Endotracheal Intubation in Critically Ill Patients Undergoing Gastrointestinal Endoscopy Under Conscious Sedation
Seisa, Mohamed O. , Deangelis, Jillian, Schroeder, Darrell R. , Diedrich, Daniel A. , Smischney, Nathan J. , Schroeder, Darrell , Kumar, Mukesh

Mayo Clinic

Journal of Intensive Care Medicine | October 19, 2017 | Volume: 34 | Issue: 6 | Pages: 480-485

10.1177/0885066617736256 | PMID 29046107 Get It

Objectives: Our primary aim was to determine the factors leading to prophylactic endotracheal intubation in intensive care unit (ICU) patients undergoing gastrointestinal endoscopy. Secondary aims were to determine the rate of unplanned endotracheal intubations during endoscopy and to determine the rate of aspiration following endoscopy for patients admitted to the ICU. Methods: Critically ill adult (≥18 years) patients who underwent upper and lower endoscopic procedures from January 2012 to July 2016 in a medical/surgical ICU were included. Determinants of prophylactic endotracheal intubation prior to endoscopy as well as other postprocedure outcomes were electronically captured by a validated data mart system. Given our focus on aspiration in those who were not endotracheally intubated prior to endoscopy, we used a validated definition a priori. Results: A total of 320 patients were included in the final analysis: 76(24%) were intubated prior to endoscopy and 244 (76%) were not. The endotracheally intubated group had a significantly higher Acute Physiologic and Chronic Health Evaluation III (44.5 [16.2] vs 39.5 [15.5]; P = .02) and Sequential Organ Failure Assessment (6.9 [4.4] vs 3.8 [3]; P ≤ .01) scores, higher rate of hematemesis within 24 hours of endoscopy (28 [37%] vs 45 [18%]; P ≤ .01), and higher rate of upper endoscopy (72 [96%] vs 181 [74%]; P ≤ .01). We composed a composite outcome for multivariable analyses, which demonstrated the rate of any complication was significantly higher among those who were intubated prior to the procedure versus those who were not intubated previously (odds ratio: 2.80, 95% confidence interval (CI): 1.16-6.72, P = .02). Conclusion: Endoscopy performed in the ICU without endotracheal intubation is safe. However, patient selection for prophylactic intubation prior to endoscopy is of critical importance as illustrated in this study with higher illness severity, planned upper endoscopy, and hematemesis 24 hours prior being key factors on deciding to perform endotracheal intubation. Prophylactic intubation for endoscopy and preexisting cardiac disease were associated with a higher rate of adverse outcomes.
Relationship of circulating spexin with markers of cardiovascular disease: a pilot study in adolescents with obesity
Kumar, Seema , Hossain, Jobayer , Javed, Asma , Balagopal, Prabhakaran , Kullo, Iftikhar J.

Mayo Clinic

Pediatric Obesity | October 18, 2017 | Volume: 13 | Issue: 6 | Pages: 374-380

10.1111/ijpo.12249 | PMID 29045048 Get It

SummaryPurposeSpexin, a novel peptide, has potential implications in obesity, satiety and energy homeostasis. The current study examined the relationship of spexin with various biomarkers of cardiovascular disease and endothelial function in adolescents with obesity.MethodsNineteen adolescents with obesity (age, 15.8 ± 1.7 years) were studied. Spexin, leptin and various cardiovascular disease biomarkers were measured. Endothelial function was assessed by high‐resolution Doppler ultrasonography of the right brachial artery.ResultsSpexin concentration (median [interquartile range] 0.38 ng/mL [0.29–0.59 ng/mL]) was inversely correlated (r = −0.50, P = 0.03) with leptin. When participants were clustered into two groups (‘high spexin and low leptin’ vs. ‘low spexin and high leptin’), the odds of having ‘low spexin and high leptin’ in participants with higher hs‐CRP (≥ 3 mg/L) were 12.25 times (95 per cent CI −1 to139, P = 0.026) higher than those of participants with lower hs‐CRP (<3 mg/L). Spexin levels, however, were not associated with measures of endothelial function.ConclusionsThe inverse association between spexin and leptin and the presence of higher concentrations of hs‐CRP in adolescents with obesity in the setting of ‘low spexin and high leptin’ suggest a potential role for spexin in the regulation of satiety and certain cardiovascular risk factors in children with obesity.
Long-term outcomes of tissue-based ACTH-antibody assay–guided transsphenoidal resection of pituitary adenomas in Cushing disease
Erfe, J. Mark, Perry, Avital , McClaskey, J H, Inzucchi, Silvio E. , James, Whitney S., Bronen, Richard A. , Hüttner, Anita , Santos, Florecita, Spencer, Dennis D. , Eid, Tore , Mahajan, Amit Kumar

Mayo Clinic

Journal of Neurosurgery | October 13, 2017 | Volume: 129 | Issue: 3 | Pages: 629-641

10.3171/2017.3.jns162245 | PMID 29027854 Get It

OBJECTIVECushing disease is caused by a pituitary micro- or macroadenoma that hypersecretes adrenocorticotropic hormone (ACTH), resulting in hypercortisolemia. For decades, transsphenoidal resection (TSR) has been an efficacious treatment but with certain limitations, namely precise tumor localization and complete excision. The authors evaluated the novel use of a double-antibody sandwich assay for the real-time quantitation of ACTH in resected pituitary specimens with the goals of augmenting pathological diagnosis and ultimately improving long-term patient outcome.METHODSThis study involved a retrospective review of records and an analysis of assay values, pathology slides, and MRI studies of patients with Cushing disease who had undergone TSR in the period from 2009 to 2014 and had at least 1 year of follow-up in coordination with an endocrinologist. In the operating room, biopsy specimens from the patients had been analyzed for tissue ACTH concentration. Additional samples were simultaneously sent for frozen-section pathological analysis. The ACTH assay performance was compared against pathology assessments of surgical tumor samples using receiver operating characteristic (ROC) analysis and against pre- and postoperative MRI studies.RESULTSFourteen patients underwent TSR with guidance by ACTH-antibody assay and pathological assessment of 127 biopsy samples and were followed up for an average of 3 years. The ACTH threshold for discriminating adenomatous from normal tissue was 290,000 pg/mg of tissue, based on jointly maximized sensitivity (95.0%) and specificity (71.3%). Lateralization discordance between preoperative MRI studies and surgical visualization was noted in 3 patients, confirming the impression that MRI alone may not achieve optimal localization. A majority of the patients (85.7%) attained long-term disease remission based on urinary free cortisol levels, plasma cortisol levels, and long-term corticosteroid therapy. Comparisons of patient-months of remission and treatment failure showed that the remission rate in the study sample statistically exceeds the rate in historical controls (71.9%; p = 0.0007, Fisher’s exact test). Long-term unexpected hormonal deficiencies were statistically similar between study patients (29%) and those in a meta-analysis (25%; p = 0.7596, Fisher’s exact test).CONCLUSIONSThese preliminary findings reflect the promising potential of tissue-based ACTH-antibody–guided assay for improving the cure rates of Cushing disease patients undergoing TSR. Further studies with larger sample sizes, further refinements of assay interpretation, and longer-term follow-ups are needed.
Minimal residual disease analysis in myeloma – when, why and where
Yanamandra, Uday , Kumar, Shaji

Mayo Clinic

Leukemia & Lymphoma | October 11, 2017 | Volume: 59 | Issue: 8 | Pages: 1772-1784

10.1080/10428194.2017.1386304 | PMID 29019452 Get It

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Kumar, Shaji , Gasparetto, Cristina , Vij, Ravi , Pegourié, Brigitte, Benboubker, Lofti, Amiot, Martine , Moreau, Philippe , Punnoose, Elizabeth A. , Alzate, Stefanie, Dunbar, Martin, Xu, Tu , Agarwal, Suresh , Enschede, Sari H., Maciag, Paulo , Verdugo, Maria, Touzeau, Cyrille , Mıkhael, Joseph , Moreau, Philippe , Touzeau, Cyrille , Kaufman, Jonathan L. , Benboubker, Lotfi , Facon, Thierry T.F. , Leverson, Joel D. , Ross, Jeremy A.

Mayo Clinic

Blood | October 10, 2017 | Volume: 130 | Issue: 22 | Pages: 2401-2409

10.1182/blood-2017-06-788786 | PMID 29018077 Get It

Key Points Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile in patients with relapsed/refractory MM. Venetoclax monotherapy has demonstrated antimyeloma activity in patients with relapsed/refractory MM positive for t(11;14).
Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population‐based nested case‐control study
Kumar, Swarup , Schleck, C. D., Johnson, Michele L., Alexander, J.A., Katzka, David A. , Iyer, Prasad G. , Kumar, S , Iyer, P G , Drake, Matthew T. , Alexander, J. A.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 5, 2017 | Volume: 46 | Issue: 11-12 | Pages: 1094-1102

10.1111/apt.14345 | PMID 28980336 Get It

SummaryBackgroundProton pump inhibitors (PPI) are inconsistently associated with osteoporotic fractures. Barrett's oesophagus (BO) patients are treated with high PPI doses for prolonged periods, but there are limited data on the incidence of osteoporosis and fractures in this group pf patients.AimTo estimate the incidence of (and risk factors for) low bone mass (osteoporosis and/or osteopenia) related fractures in a population‐based BO cohort.MethodsAll subjects with BO and a diagnosis of osteoporosis and fractures were identified using Rochester Epidemiology Project resources. The incidence rates of all and osteoporotic fractures in these subjects were compared to an age‐ and gender similar population in Olmsted County to determine standardised incidence ratios (SIR). Predictors were assessed using Cox proportional hazards models.ResultsFive hundred and twenty‐one patients were included (median [IQR] age 61 [52, 72] years; 398 [76%] men) of whom 113 (21.7%) had fractures, and 46 (8.8%) had osteoporotic fractures. The incidence of all fractures and osteoporotic fractures was comparable to that of an age‐ and gender‐matched population (SIR 1.09; 95% CI 0.92‐1.29: SIR 1.05; 95% CI 0.85‐1.29). PPI use, dose or duration of use was not associated with osteoporotic fracture risk (HR 0.87; 95% CI 0.12‐6.39). Independent risk factors for osteoporotic fractures included older age, female gender and higher co‐morbidity index.ConclusionsThe incidence of osteoporotic fractures was not increased in BO patients compared to the general population. In addition, PPI use was not associated with increased fracture risk regardless of the duration of therapy or dose.
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)
Tandon, Nidhi , Sidana, Surbhi , Lacy, Martha Q. , Dingli, David , Fonder, Amie , Hayman, Suzanne R. , Hwa, Yi L. , Hobbs, Miriam, Kapoor, Prashant , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Lust, John A., Russell, Stephen J. , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Fonder, Amie L, Hwa, Yi Lisa, Gonsalves, Wilson , Leung, Nelson , Go, Ronald S , Russell, Stephen J , Sidana, Surbhi , Dingli, David , Dispenzieri, Angela , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | September 27, 2017 | Volume: 93 | Issue: 1 | Pages: 17-22

10.1002/ajh.24919 | PMID 28960427 Get It

AbstractAchievement of a normal FLC ratio (FLCr) following treatment indicates hematologic response and suggests better outcomes in light chain amyloidosis (AL). We examined if elevated involved free light chain (hiFLC) impacts outcomes in patients achieving normal FLCr. We retrospectively analyzed 345 AL patients who were diagnosed within a 10‐year period (2006‐2015) and had 2 consecutive normal FLCr values after 1st line treatment. Among these, patients with hiFLC at 1st reading of normal FLCr (hiFLC1; n = 166; 48.1%) were compared to those who did not (n = 179; 51.9%). Patients with AL who have hiFLC1 after initial therapy had higher rates of multi‐organ involvement (63.3 vs 46.4%; P = .002) and patients in advanced Mayo stage (42.9 vs 32.2%; P = .04) at diagnosis. The median progression free survival [PFS; 38.2 (95%CI; 26.4, 55.4) vs 67.1 (95%CI; 55.8, 88) months; P = .0002] and overall survival [OS; 94.4 (95%CI; 78, 107.1) vs not reached (NR, 95%CI; 116.1, NR) months; P < .0001] were lower in those who had hiFLC1. A more stringent comparison for patients with 2 consecutive hiFLC (hIFLC2; n = 111; 32.2%) versus not (n = 2234; 67.8%) showed consistent results [PFS; 27.1 (95%CI; 23, 53.8) vs 63.3 (95%CI; 55.4, 77) months; P < .0001 and OS; 78 (95% CI; 54.6, 98.8) vs NR (95%CI; NR, NR); P < .0001]. This poor prognostic impact of hiFLC on survival was independent of serum creatinine, Mayo stage, negative immunofixation status and inclusion of transplant in initial therapy on multivariate analysis. Hence, persistent elevation of iFLC predicts poor prognosis even among patients achieving normal ratio after initial therapy in AL.